Choate, Hall & Stewart LLP’s Post

ICYMI: Over the weekend, we had Yetter Coleman LLP partner Matthew Zorn on The Dales Report to help us break down a recently released government drug policy document. 👉 How did this once-confidential report make its way into public hands? 👉 What does it say about cannabis and the DEA's stance on it? 👉 What implications could this have on US drug policy going forward? All this and more at the link in the comments. #cannabislaw #drugpolicy #cannabisreform

For the first time, the Biden Administration is proposing a framework to consider drug prices when deciding on march-in rights under the Bayh-Dole Act. This is sure to generate much debate and litigation. Stay tuned for updates! #BidenAdministration #DrugPricing #BayhDoleAct

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/fpy550SSfgn #whitecase

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/LtLx50STfFb #whitecase

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/jWIW50SSiMj #whitecase

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/FKhC50SThXH #whitecase

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/C0lS50SSlPu #whitecase

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/BqWA50SSf2c #whitecase

It has been a busy year for issues related to drug pricing, and with the election around the corner, litigation issues that have been developing over the last few years are likely to be a key focus for the second half of 2024. The White & Case team analyzes these developments and their implications for the industry in their latest alert. https://ow.ly/Qm9E50STHL2 #whitecase

Learn about jurisdiction regarding federal vs state drug charges.